Furthermore, it is still not well understood whether some of the beneficial metabolic effects (that is, reduction of glucose intolerance, dyslipoproteinaemia and hypertriglyceridaemia) of Rimonabant as well as of neutral CB1 antagonists2, 4 are merely because of the concomitant reduction of body weight or direct actions on peripheral tissues such as the adipose tissue, pancreas and skeletal muscle.5 This evidence concerns the gene CNR1 and Glucose intolerance.